FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
about
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationUnraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based TherapeuticsIntravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal MiceClinical use of Bevacizumab in treating refractory glaucomaNeonatal Fc receptor and IgG-based therapeuticsPlanar microdevices enhance transport of large molecular weight molecules across retinal pigment epithelial cells.Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheepNeonatal Fc receptor: from immunity to therapeuticsSystemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMDPreclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumabImmunoglobulin g (IgG) expression in human umbilical cord endothelial cells.Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurityTargeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicinesIntraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model.Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography.An anti-TNF-α antibody mimetic to treat ocular inflammation.Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.Clinical pharmacology of intravitreal anti-VEGF drugs.Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties.
P2860
Q24193614-0B70FFCF-A064-4298-8FFE-968FBA6AE5E4Q27027238-EFB240D6-91FD-48A2-9A99-E8A03ADE8557Q27301339-230FA2E0-EA71-4539-AEA8-F3B956E43E2AQ28083405-518A44D7-BD7A-41C3-9E53-8E67AF28E95FQ28252134-82990362-A87D-4E6F-963D-E130883ECAC4Q33849404-980864A2-397D-459B-A89C-D8606AF7A343Q33912465-22A98858-91F3-4610-95F5-54CC5E03A9B9Q34268801-2AFD5EE2-D7F4-4A01-B7CE-ABF4C702FEE9Q34608306-19B5F615-AA98-4464-A22D-EF67CA9309A6Q35226694-B07D9B04-EABB-44A8-A050-3A819BD1BF3AQ35441190-DE7CE184-07AD-41FB-B764-FC93BA4E37F2Q35851949-152AD259-84C9-4F87-A922-B9FD94FC8C81Q36164238-C32D5949-4A03-4EA4-B09E-CE26AB6E83B7Q36374429-0FE99185-E0BE-44C5-8923-E7D536655847Q36752250-FFEFC7E3-8C4D-4B07-ADA6-7E30CABEA906Q37361023-43955EF4-8C72-4747-A642-A5AADF646941Q37428259-859940D9-AAE5-481E-8E5C-7073492D4153Q37549985-68D8364F-F815-432C-992F-9A1D1C098CD3Q38170235-88A7216E-35F1-4F77-A1F6-EC38CB0D6DE9Q38587550-3D7E5993-2891-4AF9-9CF7-175EEA32356EQ48109878-51B3D74D-9F08-4526-B888-029D3372E11EQ48515898-4CF6CA6C-8660-4F50-A05C-F2AB4FE8FB18
P2860
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
@ast
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
@en
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
@nl
type
label
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
@ast
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
@en
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
@nl
prefLabel
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
@ast
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
@en
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
@nl
P2093
P2860
P1433
P1476
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.
@en
P2093
Hyuncheol Kim
Karl G Csaky
Shaun B Robinson
P2860
P304
P577
2009-12-16T00:00:00Z